Novartis AG (SIX: NOVN; NYSE: NVS), a global leader in immunology and targeted therapies, has broadened its partnership with Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) to co-develop a new generation of molecular glue degraders (MGDs) designed for immune-mediated diseases. The collaboration reinforces Novartis’ strategy of harnessing cutting-edge platforms such as artificial intelligence and protein degradation to address high unmet need in immunology.
Agreement Highlights
- Exclusive License: Novartis obtains exclusive rights to one undisclosed immune target.
- Options to Expand: The company secures options to license two additional preclinical programs from Monte Rosa’s pipeline.
- Financial Structure: Monte Rosa receives $120 million upfront, option maintenance payments, and could earn up to $5.7 billion in potential option, development, regulatory, and commercial milestones. Tiered royalties on global net sales are also included.
This agreement follows the 2024 global license Novartis secured for Monte Rosa’s VAV1 degrader program, including MRT-6160, which is advancing toward multiple Phase 2 trials.
Novartis’ Strategic Positioning
Fiona Marshall, Ph.D., President of Biomedical Research at Novartis, emphasized:
“Expanding our collaboration with Monte Rosa demonstrates Novartis’ long-term commitment to targeted protein degradation as a therapeutic modality. By integrating Monte Rosa’s AI/ML-enabled QuEEN™ discovery engine with our own global development and commercialization capabilities, we can accelerate the creation of therapies that reach patients faster and set new standards in immune-mediated disease treatment.”
The deal underscores Novartis’ broader R&D strategy:
- Building one of the most advanced immunology & inflammation portfolios in the industry.
- Investing in AI-driven discovery engines to unlock “undruggable” targets.
- Leveraging its global scale to commercialize novel medicines rapidly and effectively.
Monte Rosa’s Role in the Partnership
Monte Rosa brings its QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform, which integrates AI-guided chemistry, structural biology, and proteomics. This discovery engine has already generated a robust pipeline of preclinical and clinical candidates across autoimmune, inflammatory, and oncology indications.
Monte Rosa CEO Markus Warmuth, M.D., noted:
“Novartis’ deep expertise in immune-mediated diseases and their global reach make them the ideal partner to accelerate the translation of our molecular glue degrader programs. Together, we can pursue historically undruggable targets and build an entirely new class of therapies.”
Broader Industry Impact
With this deal, Novartis positions itself as a front-runner in the race to bring molecular glue degraders into mainstream immunology practice. Analysts note that the potential $5.7 billion deal value reflects both the scientific ambition and commercial potential of this collaboration, particularly as the field of targeted protein degradation becomes a key battleground for big pharma innovation.
Next Steps
The companies will prioritize undisclosed immune-mediated disease programs while Monte Rosa advances its wholly owned pipeline, including MRT-8102, MRT-6160, and MRT-2359. Novartis is expected to play a central role in late-stage clinical development and eventual commercialization.
About the Companies:
Novartis is a leading global medicines company, focused on addressing unmet medical needs through innovation in pharmaceuticals and advanced therapeutics.
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing selective molecular glue degrader medicines, powered by its AI/ML-enabled QuEEN™ discovery platform.
By
